Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ACP-196

Known as: Bruton Tyrosine Kinase Inhibitor ACP-196 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
BACKGROUND Bruton tyrosine kinase is a clinically validated target in mantle cell lymphoma. Acalabrutinib (ACP-196) is a highly… Expand
Is this relevant?
Highly Cited
2017
Highly Cited
2017
Several small-molecule Bruton tyrosine kinase (BTK) inhibitors are in development for B cell malignancies and autoimmune… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2017
2017
Acalabrutinib is a new, irreversible Bruton tyrosine kinase (BTK) inhibitor, reported to be more selective than ibrutinib.[1][1… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2016
Highly Cited
2016
BACKGROUND Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
2016
2016
4130Background: The importance of the tumor microenvironment in the biology of mPC has been increasingly recognized. However… Expand
Is this relevant?
Highly Cited
2016
Highly Cited
2016
Purpose: Acalabrutinib (ACP-196) is a novel, potent, and highly selective Bruton tyrosine kinase (BTK) inhibitor, which binds… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
Ibrutinib, a first generation Btk inhibitor, is approved for the treatment of CLL and mantle cell lymphoma; known toxicities… Expand
Is this relevant?
2015
2015
Background: Signaling through the B-cell receptor (BCR) results in cell survival and proliferation, and this pathway is critical… Expand
Is this relevant?
2014
2014
Background: Targeting Bruton9s tyrosine kinase (BTK), an essential kinase in the B cell receptor (BCR) pathway in patients with… Expand
Is this relevant?
2014
2014
Recent recognition of B-cell receptor (BCR) signaling as a critical factor in the progression of B-cell malignancies, including… Expand
Is this relevant?